Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03798301 · ClinicalTrials.gov registry record · Phase 1
Treatment of Cytomegalovirus (CMV) Infections With Viral-Specific T Cells
A Phase 1 study, sponsored by University of Wisconsin, Madison.
- Terminated
- Registry status
- Phase 1
- Development phase
- 3
- Enrollment target
NCT03798301: Clinical Trial Phase 1 study, sponsored by University of Wisconsin, Madison.
NCT03798301 is a Phase 1 study that was terminated before completion, run by University of Wisconsin, Madison. The registered enrollment target is 3 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (95% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03798301, a Phase 1 study, was terminated before completion, sponsored by University of Wisconsin, Madison.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 3 participants
- Enrollment target
Study Summary
The present trial will consist of the treatment of 20 pediatric and adult Hematopoietic Stem Cell Transplantation (HSCT) recipients or immunocompromised participants diagnosed with opportunistic Cytomegalovirus (CMV) infections with virus-specific, antigen-selected T-cells. CMV-specific T-cells will be isolated from donor leukapheresis products using the CliniMACS® Prodigy. Prior studies on transfer of CMV specific T-cells have been shown to be safe and efficacious in the treatment of CMV infections. The main trial objective is to evaluate the feasibility and safety of CMV-specific T-cell transfer in adult and pediatric participants suffering from CMV infections or reactivation following HSCT or due to other immunocompromised states (e.g.; primary immunodeficiency, cytotoxic therapy). Participants will be followed for one year.
Primary Outcome
The feasibility of this intervention will in part be accomplished by measuring the number of dropped out participants before T-Cell Transfer.
Interventions
- BIOLOGICAL CMV-specific T-cells
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2020-02-06 |
| Est. Completion | 2023-05-31 |
| Phase | Phase 1 |
Why NCT03798301 stopped before completion
NCT03798301 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 3 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (95% lower).
The record links to 0 conditions, and to 1 intervention - of which CMV-specific T-cells is the first listed.
NCT03798301 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03798301 about?
NCT03798301 is a clinical study titled "Treatment of Cytomegalovirus (CMV) Infections With Viral-Specific T Cells". The present trial will consist of the treatment of 20 pediatric and adult Hematopoietic Stem Cell Transplantation (HSCT) recipients or immunocompromised participants diagnosed with opportunistic Cytomegalovirus (CMV) infections with virus-specific, antigen-selected T-cells. CMV-specific T-cells will...
What is the current status of trial NCT03798301?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 3 participants. The study started on 2020-02-06. Estimated completion is 2023-05-31.
What interventions are being tested in trial NCT03798301?
The interventions under investigation include: CMV-specific T-cells (BIOLOGICAL).
Who is sponsoring clinical trial NCT03798301?
This trial is sponsored by University of Wisconsin, Madison, which has 1,039 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03798301's enrollment target sits among peer trials
3 1999th of 2000 higher than 1 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI